Encore Medical Corporation Announces Third Quarter 2006 Earnings Conference Call and Webcast
October 12 2006 - 3:22PM
PR Newswire (US)
AUSTIN, Texas, Oct. 12 /PRNewswire-FirstCall/ -- Encore Medical
Corporation (NASDAQ:ENMC) announced today that the Company will
release third quarter 2006 financial results prior to the opening
of trading on Thursday, October 26, 2006. The Company will then
host a conference call beginning at 10 am Eastern Time to discuss
the results of operations and recent business developments. A live
webcast of the conference can be accessed from Encore's website
http://www.encoremed.com/ . If you are unable to participate during
the live webcast, an audio archive will be available shortly after
the call and will be accessible from Encore's website for
approximately 30 days. A telephonic replay of the conference call
will also be available for one week after the call by dialing
(domestic) (800) 642-1687 or (international) (706) 645-9291 and
requesting conference ID #8726127. Encore Medical Corporation is a
diversified orthopedic device company that develops, manufactures
and distributes a comprehensive range of high quality orthopedic
devices used by orthopedic surgeons, physicians, therapists,
athletic trainers and other healthcare professionals to treat
patients with musculoskeletal conditions resulting from
degenerative diseases, deformities, traumatic events and
sports-related injuries. Through its Orthopedic Rehabilitation
Division, Encore is a leading distributor of electrical stimulation
and other orthopedic products used for pain management, orthopedic
rehabilitation, physical therapy, fitness and sport performance
enhancement. Encore's Surgical Implant Division offers a
comprehensive suite of reconstructive joint products and spinal
implants. Contact: William W. Burke, Executive Vice President -
Chief Financial Officer (512) 832-9500 Media: Davis Henley, Vice
President - Business Development (512) 832-9500 Important
Information In connection with the proposed merger among Grand Slam
Holdings, LLC, Grand Slam Acquisition Corp., which are affiliates
of Blackstone Capital Partners V L.P., and Encore, pursuant to the
Agreement and Plan of Merger, dated as of June 30, 2006, Encore
filed its definitive proxy statement with the Securities and
Exchange Commission on October 3, 2006. THIS DOCUMENT CONTAINS
IMPORTANT INFORMATION ABOUT THE TRANSACTION, AND ENCORE URGES YOU
TO READ THESE DOCUMENTS. In addition to receiving the proxy
statement from Encore by mail, stockholders may obtain the proxy
statement, as well as other filings containing information about
Encore, without charge, from the Securities and Exchange
Commission's website (http://www.sec.gov/) or, without charge, from
Encore at http://www.encoremed.com/. This announcement is neither a
solicitation of proxy, an offer to purchase nor a solicitation of
an offer to sell shares of Encore. Except for the historical
information contained herein, the matters discussed are
forward-looking statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
These statements involve risks and uncertainties, such as quarterly
fluctuations in operating results, the timely availability of new
products, the impacts of competitive products and pricing, the
ability to grow the distribution networks for Encore's products,
the ability to continue to obtain long-term financing, and the
ability to locate and integrate past and future acquisitions. Risks
and uncertainties related to Encore's acquisition by Blackstone
Capital Partners include Encore not being able to complete the
proposed transaction, conditions in the financing commitments that
could impact the ability to obtain long-term financing, failure to
obtain acceptances to its proposed debt tender offer, and
stockholder or other regulatory approvals or to satisfy other
closing conditions, the possibility of the occurrence of an event
that could constitute a Company Material Adverse Effect as defined
in the merger agreement. Additionally, the Company is subject to
other risks and uncertainties set forth in the Company's filings
with the Securities and Exchange Commission. These risks and
uncertainties could cause actual results to differ materially from
any forward-looking statements made herein. Encore and certain of
its affiliates may be deemed to be participants in the solicitation
of proxies in connection with the proposed transaction. A
description of the interests of certain of Encore's directors and
executive officers in Encore is set forth in Encore's annual report
on Form 10-K for the fiscal year ended December 31, 2005.
Additional information regarding the persons who may, under the
rules of the SEC, be deemed participants in the solicitation of
proxies in connection with the proposed transaction, and a
description of their interests in the proposed transaction, as well
as the interests of Encore's executive officers and directors, are
set forth in Encore's proxy statement for its 2006 annual meeting
filed with the SEC on April 12, 2006, and in the definitive proxy
statement filed with the SEC on October 3, 2006. DATASOURCE: Encore
Medical Corporation CONTACT: William W. Burke, Executive Vice
President - Chief Financial Officer, +1-512-832-9500, , or Media:
Davis Henley, Vice President - Business Development,
+1-512-832-9500, , both of Encore Medical Corporation Web site:
http://www.encoremed.com/
Copyright
Encore Medical (NASDAQ:ENMC)
Historical Stock Chart
From Oct 2024 to Nov 2024
Encore Medical (NASDAQ:ENMC)
Historical Stock Chart
From Nov 2023 to Nov 2024